BPOM Authorizes Use Of Zifivax Covid-19 Vaccine

Translator:

Editor:

Mahinda Arkyasa

  • Font:
  • Ukuran Font: - +
  • TEMPO.CO, Jakarta - The Food and Drugs Monitoring Agency (BPOM) has issued an emergency use authorization (EUA) for the Zifivax Covid-19 vaccine on Thursday, October 7, 2021. 

    "Results from the phase 1, 2, and 3 clinical trials of Zifivax vaccines resulted in 81.71 percent efficacy seven days after complete vaccination," said BPOM chairperson Penny Lukito in a press conference on Thursday, October 7, 2021. 

    Subjects will be given three doses of the vaccine through intramuscular injections within one month with 0.5 ml of the vaccine in each shot. 

    In facing the new Covid-19 variants, according to Penny Lukito, Zifivax produced 92.93 percent efficacy against the Alpha variant, 100 percent against Gamma, 77.47 percent against Delta, and 90 percent against Kappa variant. 

    Side effects caused by the vaccine’s injection are considered to be under tolerable levels such as muscle soreness in the area of injection, headaches, and fever. The vaccines can be stored under 2 to 4 degrees Celsius temperature, which the BPOM chief said fits a tropical country such as Indonesia. Zifivax was developed by Chinese firm Anhui Zhifei Longcom Biopharmaceutical.

    SYAHARANI PUTRI